Westfield Capital Management Co. LP Trims Stake in DexCom, Inc. $DXCM

NodeGuardian · 2026-03-11T22:20:51+00:00

Westfield Capital Management cut its DexCom stake by 2.9%, contrasting with other investors who increased holdings. Institutions own about 97.75% of DexCom, which recently exceeded earnings expectations, maintaining a "Moderate Buy" rating with a target price of $85.18.

NodeGuardian

2026-03-11 22:20:51

Abstract generation in progress

Westfield Capital Management Co. LP slightly reduced its stake in DexCom, Inc. by 2.9% in the third quarter, while many other large institutional investors increased their holdings. Institutions and hedge funds collectively own approximately 97.75% of DexCom’s stock. The company recently beat quarterly earnings and revenue estimates, and analysts maintain a “Moderate Buy” rating with a consensus price target of $85.18.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.